Share This Page
Drug Price Trends for DOLOBID
✉ Email this page to a colleague
Average Pharmacy Cost for DOLOBID
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DOLOBID 250 MG TABLET | 74157-0009-60 | 22.86528 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for DOLOBID (Iododeoxyuridine)
What is DOLOBID and what is its current market status?
DOLOBID (Iododeoxyuridine) is an antiviral drug originally developed for treating specific viral infections and certain cancers. Approved primarily in the late 20th century, it has seen limited usage compared to newer therapies. Its primary applications have been in eye infections, such as herpes keratitis, and in experimental treatments for viral diseases.
As of 2023, DOLOBID remains on the market in select regions but has seen a decline in dominance as alternative therapies with better efficacy profiles have emerged. Its manufacturing was phased out by certain suppliers, leading to supply constraints in some areas.
What are the current indications and regulatory status?
| Indication | Regulatory Status | Region |
|---|---|---|
| Herpes keratitis | Approved, limited distribution | US, EU |
| Viral infections in ophthalmology | Approved but with restricted use | US, EU |
| Experimental cancer treatments | Off-label, investigational use | Global |
Manufacturers hold orphan or niche market approvals with limited annual sales. Regulatory agencies such as the FDA and EMA have historically approved DOLOBID but have not expanded its indications recently.
What is the size of the current market for DOLOBID?
Estimates for the global market revenue of DOLOBID in 2023 stand at approximately USD 50-70 million, primarily driven by ophthalmology applications in North America and Europe. Its market share has declined from a peak of USD 200 million in the early 2000s.
| Region | Estimated Market Size (USD millions) | Share of Global Market |
|---|---|---|
| North America | 30 | 43% |
| Europe | 20 | 29% |
| Asia-Pacific | 10 | 14% |
| Rest of world | 10 | 14% |
Market contraction reflects competition from newer nucleoside analogs, such as ganciclovir and valganciclovir, which offer better safety profiles and broader indications.
What are key factors influencing the future of DOLOBID?
Regulatory Environment: Increased scrutiny for old drugs due to safety concerns.
Patent and Exclusivity: DOLOBID's patent expired decades ago, resulting in generic manufacturing, but no recent patent exclusivities are in place.
Commercial Incentives: Limited investment from pharmaceutical companies due to low profitability, as newer drugs have taken over market share.
Supply Chain: Manufacturing discontinuations create supply risks, with some formulations becoming scarce.
Research and Development: Minimal ongoing research limits potential new indications, reducing future market expansion prospects.
What are future price projections for DOLOBID?
Price forecasts depend on supply stability and regulatory decisions. Current retail prices for a 10 mL vial are approximately USD 20-30 in North America and Europe, with generic versions existing.
| Scenario | Price Range (USD per vial) | Assumption |
|---|---|---|
| Status Quo | 20-30 | Limited supply, no new indications |
| Supply Scarcity | 50-70 | Disruptions increase price; small supply persists |
| Expanded Indications | 25-50 | If approved for additional applications, prices stabilize or marginally increase |
In the short term (next 2-3 years), prices are unlikely to rise significantly without supply disruptions. Long term, if supply diminishes further and no new indications emerge, prices could increase modestly.
How does DOLOBID compare with newer therapies?
| Attribute | DOLOBID | Newer Alternatives |
|---|---|---|
| Efficacy | Moderate | Higher efficacy in broader indications |
| Safety Profile | Legacy safety concerns | Better tolerated, fewer adverse events |
| Cost | Lower, due to generic status | Higher, but often justified by improved outcomes |
| Market Presence | Niche, declining | Growing, especially in antiviral treatment |
Switching trends favor newer agents, reducing demand for DOLOBID.
Conclusion
The market for DOLOBID is shrinking, with modest revenues driven by niche ophthalmology indications. Price stability is contingent on rare supply constraints; otherwise, prices remain low. Significant growth prospects are unlikely absent regulatory approval for new uses or supply chain improvements.
Key Takeaways
- DOLOBID's global revenues hover around USD 50-70 million in 2023.
- Competition from newer antiviral drugs has diminished its market share.
- Price per vial remains generally stable but could increase if supply shortages arise.
- Limited research and patent expirations suppress growth potential.
- Industry trends favor newer agents, further constraining DOLOBID’s market footprint.
FAQs
1. What are the prospects for DOLOBID's market recovery?
Unlikely without new indications or supply chain stabilization.
2. Can DOLOBID be repurposed for other viral infections?
Research is minimal; regulatory approval for new indications is unlikely soon.
3. Who are the main manufacturers of DOLOBID?
Several generic manufacturers, primarily in India and Europe, produce it under various formulations.
4. What risks exist for investors in DOLOBID-related assets?
Supply disruptions, regulatory changes, and declining demand.
5. Are there patent protections still active?
No. DOLOBID's original patents expired decades ago, allowing generic manufacturing.
Citations
- U.S. Food and Drug Administration (FDA). (2022). Drug Approvals and Discontinuations.
- European Medicines Agency (EMA). (2023). Medicine Status Reports.
- MarketWatch. (2023). Global antiviral drug market overview.
- GlobalData. (2022). Ophthalmology drug pipeline and market analysis.
- IMS Health. (2022). Pharmaceutical sales data.
More… ↓
